Inflammation	inflammation	NN	O
is	be	VBZ	O
a	a	DT	O
protective	protective	JJ	O
host	host	NN	O
immune	immune	JJ	O
response	response	NN	O
to	to	IN	O
noxious	noxious	JJ	O
stimuli	stimulus	NNS	O
,	,	,	O
injury	injury	NN	O
,	,	,	O
or	or	CC	O
infection	infection	NN	B
.	.	.	O

Long	long	JJ	O
-	-	HYPH	O
term	term	NN	O
chronic	chronic	JJ	O
inflammation	inflammation	NN	O
,	,	,	O
however	however	RB	O
,	,	,	O
can	can	MD	O
cause	cause	VB	O
increased	increase	VBN	O
vascular	vascular	JJ	O
permeability	permeability	NN	O
,	,	,	O
fibrosis	fibrosis	NN	O
,	,	,	O
and	and	CC	O
tissue	tissue	NN	O
damage	damage	NN	O
and	and	CC	O
can	can	MD	O
lead	lead	VB	O
to	to	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
metabolic	metabolic	JJ	O
disorders	disorder	NNS	O
such	such	JJ	O
as	as	IN	O
rheumatoid	rheumatoid	NNP	O
arthritis	arthritis	NN	O
,	,	,	O
atherosclerosis	atherosclerosis	NN	O
,	,	,	O
and	and	CC	O
even	even	RB	O
cancer	cancer	NN	B
,	,	,	B
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
well	well	RB	O
known	know	VBN	O
that	that	IN	O
the	the	DT	O
use	use	NN	O
of	of	IN	O
chemical	chemical	JJ	O
drugs	drug	NNS	O
to	to	TO	O
inhibit	inhibit	VB	O
inflammation	inflammation	NN	O
is	be	VBZ	O
an	an	DT	O
effective	effective	JJ	O
way	way	NN	O
to	to	TO	O
alleviate	alleviate	VB	O
the	the	DT	O
symptoms	symptom	NNS	O
of	of	IN	O
inflammation	inflammation	NN	O
-	-	HYPH	O
related	relate	VBN	O
diseases	disease	NNS	B
,	,	,	B
.	.	.	O

Nonsteroidal	nonsteroidal	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
drugs	drug	NNS	O
are	be	VBP	O
still	still	RB	O
widely	widely	RB	O
used	use	VBN	O
in	in	IN	O
clinical	clinical	JJ	O
applications	application	NNS	O
today	today	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
they	-PRON-	PRP	O
usually	usually	RB	O
cause	cause	VBP	O
unexpected	unexpected	JJ	O
side	side	NN	O
effects	effect	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
peptic	peptic	JJ	O
ulcers	ulcer	NNS	O
,	,	,	O
bleeding	bleeding	NN	O
,	,	,	O
mucosal	mucosal	NN	O
lesions	lesion	NNS	O
,	,	,	O
and	and	CC	O
nephrotoxicity	nephrotoxicity	NN	B
,	,	,	B
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
,	,	,	O
therefore	therefore	RB	O
,	,	,	O
better	well	JJR	O
to	to	TO	O
find	find	VB	O
novel	novel	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
compounds	compound	NNS	O
with	with	IN	O
fewer	few	JJR	O
adverse	adverse	JJ	O
reactions	reaction	NNS	O
.	.	.	O

As	as	IN	O
a	a	DT	O
congenital	congenital	JJ	O
immune	immune	JJ	O
cell	cell	NN	O
,	,	,	O
macrophages	macrophage	NNS	O
play	play	VBP	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
the	the	DT	O
occurrence	occurrence	NN	O
and	and	CC	O
development	development	NN	O
of	of	IN	O
inflammation	inflammation	NN	O
.	.	.	O

During	during	IN	O
inflammation	inflammation	NN	O
,	,	,	O
macrophages	macrophage	VBZ	O
overexpress	overexpress	NNP	O
bioactive	bioactive	JJ	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	O
such	such	JJ	O
as	as	IN	O
nitric	nitric	JJ	O
oxide	oxide	NN	O
,	,	,	O
interleukin	interleukin	NNP	O
6	6	CD	O
,	,	,	O
and	and	CC	O
tumour	tumour	VB	O
necrosis	necrosis	NN	O
factor	factor	NN	O
-	-	HYPH	O
alpha	alpha	NN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
)	)	-RRB-	B
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
accumulation	accumulation	NN	O
of	of	IN	O
these	these	DT	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	O
can	can	MD	O
cause	cause	VB	O
cell	cell	NN	O
and	and	CC	O
tissue	tissue	NN	O
damage	damage	NN	O
and	and	CC	O
eventually	eventually	RB	O
chronic	chronic	JJ	O
inflammation	inflammation	NN	B
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
cytokine	cytokine	JJ	O
release	release	NN	O
from	from	IN	O
activated	activate	VBN	O
macrophages	macrophage	NNS	O
is	be	VBZ	O
,	,	,	O
therefore	therefore	RB	O
,	,	,	O
an	an	DT	O
important	important	JJ	O
mode	mode	NN	O
of	of	IN	O
action	action	NN	O
of	of	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
drugs	drug	NNS	O
.	.	.	O

The	the	DT	O
mitogen	mitogen	NN	O
-	-	HYPH	O
activated	activate	VBN	O
protein	protein	NN	O
kinases	kinase	NNS	O
are	be	VBP	O
a	a	DT	O
family	family	NN	O
of	of	IN	O
signal	signal	NN	O
transduction	transduction	NN	O
proteins	protein	NNS	O
that	that	WDT	O
include	include	VBP	O
extracellular	extracellular	NNP	O
signal	signal	NN	O
-	-	HYPH	O
regulated	regulate	VBN	O
kinase	kinase	NN	O
,	,	,	O
c	c	NNP	O
-	-	:	O
Jun	Jun	NNP	O
N	N	NNP	O
-	-	HYPH	O
terminal	terminal	NN	O
kinases	kinase	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
p38	p38	NNP	O
isoform	isoform	NN	O
,	,	,	O
which	which	WDT	O
are	be	VBP	O
involved	involve	VBN	O
in	in	IN	O
the	the	DT	O
classical	classical	JJ	O
pathways	pathway	NNS	O
that	that	WDT	O
modulate	modulate	VBP	O
immune	immune	JJ	O
-	-	HYPH	O
mediated	mediate	VBN	O
inflammatory	inflammatory	JJ	O
responses	response	NNS	O
through	through	IN	O
the	the	DT	O
corresponding	corresponding	JJ	O
signalling	signalling	NN	O
cascades	cascade	VBZ	B
,	,	,	B
.	.	.	O

Activated	activate	VBN	O
MAPKs	MAPKs	NNPS	O
modify	modify	VBP	O
the	the	DT	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
the	the	DT	O
threonine	threonine	NNP	O
/	/	SYM	O
tyrosine	tyrosine	NN	O
motifs	motif	NNS	O
,	,	,	O
accelerating	accelerate	VBG	O
iNOS	inos	NN	O
,	,	,	O
COX-2	COX-2	NNP	O
,	,	,	O
and	and	CC	O
pro	pro	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
cytokine	cytokine	JJ	O
expression	expression	NN	O
including	include	VBG	O
NO	NO	NNP	O
,	,	,	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
and	and	CC	O
IL-6	il-6	JJ	O
in	in	IN	O
the	the	DT	O
activated	activate	VBN	O
macrophages	macrophage	NNS	B
.	.	.	O

Thus	thus	RB	O
,	,	,	O
the	the	DT	O
pharmacological	pharmacological	JJ	O
interference	interference	NN	O
or	or	CC	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
MAPK	MAPK	NNP	O
signalling	signalling	NN	O
pathway	pathway	NN	O
can	can	MD	O
effectively	effectively	RB	O
alleviate	alleviate	VB	O
the	the	DT	O
occurrence	occurrence	NN	O
and	and	CC	O
development	development	NN	O
of	of	IN	O
inflammation	inflammation	NN	O
.	.	.	O

Development	development	NN	O
of	of	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
agents	agent	NNS	O
that	that	WDT	O
target	target	VBP	O
the	the	DT	O
MAPK	MAPK	NNP	O
pathway	pathway	NN	O
might	may	MD	O
be	be	VB	O
an	an	DT	O
attractive	attractive	JJ	O
therapeutic	therapeutic	JJ	O
approach	approach	NN	O
.	.	.	O

In	in	IN	O
previous	previous	JJ	O
studies	study	NNS	O
,	,	,	O
we	-PRON-	PRP	O
presented	present	VBD	O
many	many	JJ	O
different	different	JJ	O
derivative	derivative	JJ	O
series	series	NN	O
with	with	IN	O
significant	significant	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activities	activity	NNS	O
in	in	IN	O
an	an	DT	O
in	in	IN	O
vivo	vivo	NNP	O
xylene	xylene	NN	O
-	-	HYPH	O
induced	induce	VBN	O
ear	ear	NN	O
-	-	HYPH	O
oedema	oedema	NN	O
model	model	NN	B
.	.	.	O

A	a	DT	O
series	series	NN	O
of	of	IN	O
6-substituted	6-substituted	CD	O
-	-	HYPH	O
triazolophthalazine-3-carboxamide	triazolophthalazine-3-carboxamide	NNP	O
derivatives	derivative	NNS	O
were	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
especially	especially	RB	O
effective	effective	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
agents	agent	NNS	O
in	in	IN	O
vitro	vitro	FW	O
and	and	CC	O
in	in	IN	O
vivo	vivo	NNP	B
.	.	.	O

Among	among	IN	O
them	-PRON-	PRP	O
,	,	,	O
compounds	compound	VBZ	O
A1	A1	NNP	B
,	,	,	O
B1	b1	NN	B
,	,	,	O
C1	C1	NNP	B
,	,	,	O
and	and	CC	O
D1	d1	NN	B
were	be	VBD	O
shown	show	VBN	O
to	to	TO	O
be	be	VB	O
the	the	DT	O
most	most	RBS	O
active	active	JJ	O
derivatives	derivative	NNS	O
in	in	IN	O
each	each	DT	O
series	series	NN	O
,	,	,	O
and	and	CC	O
their	-PRON-	PRP$	O
structures	structure	NNS	O
are	be	VBP	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

Structure	structure	NN	O
analysis	analysis	NN	O
of	of	IN	O
these	these	DT	O
derivatives	derivative	NNS	O
revealed	reveal	VBD	O
the	the	DT	O
following	follow	VBG	O
:	:	:	O
a	a	DT	O
tricyclic	tricyclic	JJ	O
skeleton	skeleton	NN	O
that	that	WDT	O
contains	contain	VBZ	O
a	a	DT	O
triazole	triazole	NN	O
ring	ring	NN	O
;	;	:	O
and	and	CC	O
a	a	DT	O
triazole	triazole	NN	O
,	,	,	O
3-amino	3-amino	CD	O
triazole	triazole	NN	O
,	,	,	O
or	or	CC	O
3-amido	3-amido	CD	O
triazole	triazole	NN	O
that	that	WDT	O
was	be	VBD	O
assumed	assume	VBN	O
to	to	TO	O
be	be	VB	O
the	the	DT	O
main	main	JJ	O
pharmacological	pharmacological	JJ	O
moiety	moiety	NN	O
conferring	confer	VBG	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effect	effect	NN	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
functional	functional	JJ	O
group	group	NN	O
transitions	transition	NNS	O
and	and	CC	O
flipping	flipping	NN	O
are	be	VBP	O
classic	classic	JJ	O
and	and	CC	O
effective	effective	JJ	O
strategies	strategy	NNS	O
for	for	IN	O
the	the	DT	O
rational	rational	JJ	O
optimisation	optimisation	NN	O
of	of	IN	O
lead	lead	NN	O
compounds	compound	VBZ	B
.	.	.	O

Design	design	NN	O
of	of	IN	O
target	target	NN	O
compounds	compound	VBZ	O
6aâ6	6aâ6	NNP	O
t	t	NN	O
.	.	.	O

As	as	IN	O
part	part	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
continuous	continuous	JJ	O
efforts	effort	NNS	O
to	to	TO	O
develop	develop	VB	O
better	well	JJR	O
novel	novel	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
agents	agent	NNS	O
and	and	CC	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
above	above	JJ	O
observations	observation	NNS	O
,	,	,	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
5-alkyl-4-oxo-4,5-dihydro-[1	5-alkyl-4-oxo-4,5-dihydro-[1	CD	O
,	,	,	O
2	2	CD	O
,	,	,	O
4]triazoloquinoxaline-1-carboxamide	4]triazoloquinoxaline-1-carboxamide	CD	O
derivatives	derivative	NNS	O
6aâ6	6aâ6	NNP	O
t	t	NNP	O
were	be	VBD	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
using	use	VBG	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
D	d	NN	O
and	and	CC	O
the	the	DT	O
design	design	NN	O
principles	principle	NNS	O
of	of	IN	O
skeleton	skeleton	NNP	O
migration	migration	NN	O
and	and	CC	O
functional	functional	JJ	O
group	group	NN	O
flipping	flipping	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effects	effect	NNS	O
of	of	IN	O
these	these	DT	O
target	target	NN	O
compounds	compound	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
following	follow	VBG	O
lipopolysaccharide	lipopolysaccharide	NN	O
-induced	-induce	VBN	O
NO	no	DT	O
production	production	NN	O
.	.	.	O

Further	further	RB	O
,	,	,	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
compound	compound	NN	O
,	,	,	O
6p	6p	CD	O
,	,	,	O
with	with	IN	O
a	a	DT	O
3,4,5-trimethoxybenzyl	3,4,5-trimethoxybenzyl	CD	O
moiety	moiety	NN	O
,	,	,	O
was	be	VBD	O
subjected	subject	VBN	O
to	to	IN	O
preliminary	preliminary	JJ	O
studies	study	NNS	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
mechanisms	mechanism	NNS	O
of	of	IN	O
action	action	NN	O
underlying	underlie	VBG	O
its	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
by	by	IN	O
western	western	JJ	O
blotting	blotting	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
we	-PRON-	PRP	O
confirmed	confirm	VBD	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effects	effect	NNS	O
in	in	IN	O
vivo	vivo	NNP	O
by	by	IN	O
using	use	VBG	O
the	the	DT	O
carrageenan	carrageenan	NNP	O
method	method	NN	O
.	.	.	O

All	all	DT	O
chemicals	chemical	NNS	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
commercial	commercial	JJ	O
source	source	NN	O
and	and	CC	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
unless	unless	IN	O
otherwise	otherwise	RB	O
stated	state	VBN	O
.	.	.	O

The	the	DT	O
reactions	reaction	NNS	O
were	be	VBD	O
monitored	monitor	VBN	O
by	by	IN	O
TLC	TLC	NNP	O
using	use	VBG	O
Merck	Merck	NNP	O
Kieselgel	Kieselgel	NNP	O
60âF	60âf	VBP	O
254	254	CD	O
plates	plate	NNS	O
and	and	CC	O
visualised	visualise	VBN	O
under	under	IN	O
UV	UV	NNP	O
light	light	NN	O
at	at	IN	O
254ânm	254ânm	CD	O
.	.	.	O

Column	column	NN	O
chromatography	chromatography	NN	O
was	be	VBD	O
generally	generally	RB	O
performed	perform	VBN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
.1H	.1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
and	and	CC	O
13C	13C	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
measured	measure	VBN	O
on	on	IN	O
an	an	DT	O
AV-300	AV-300	NNP	O
and	and	CC	O
all	all	DT	O
chemical	chemical	NN	O
shifts	shift	NNS	O
were	be	VBD	O
given	give	VBN	O
in	in	IN	O
ppm	ppm	NNP	O
relative	relative	NNP	O
to	to	IN	O
tetramethylsilane	tetramethylsilane	NN	O
.	.	.	O

High	high	JJ	O
-	-	HYPH	O
resolution	resolution	NN	O
mass	mass	NN	O
spectra	spectra	NNP	O
were	be	VBD	O
measured	measure	VBN	O
with	with	IN	O
an	an	DT	O
Thermo	Thermo	NNP	O
Scientific	Scientific	NNP	O
LTQ	LTQ	NNP	O
Orbitrap	Orbitrap	NNP	O
XL	XL	NNP	O
in	in	IN	O
ESI	ESI	NNP	O
mode	mode	NN	O
.	.	.	O

A	a	DT	O
mixture	mixture	NN	O
of	of	IN	O
benzene-1,2-diamine	benzene-1,2-diamine	NNP	O
10.0âg	10.0âg	CD	O
,	,	,	O
92âmmol	92âmmol	CD	O
,	,	,	O
oxalic	oxalic	JJ	O
acid	acid	NN	O
12.50âg	12.50âg	CD	O
,	,	,	O
139âmmol	139âmmol	CD	O
,	,	,	O
and	and	CC	O
30.00âml	30.00âml	CD	O
10	10	CD	O
%	%	NN	O
HCl	HCl	NNS	O
in	in	IN	O
30âml	30âml	CD	O
H2O	h2o	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
2âh	2âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
cooled	cool	VBN	O
and	and	CC	O
then	then	RB	O
filtered	filter	VBN	O
to	to	TO	O
obtain	obtain	VB	O
1,4-dihydroquinoxaline-2,3-dione	1,4-dihydroquinoxaline-2,3-dione	CD	O
as	as	IN	O
a	a	DT	O
white	white	JJ	O
solid	solid	JJ	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
93	93	CD	O
%	%	NN	O
,	,	,	O
m.p	m.p	NNP	O
.	.	NNP	O

>	>	XX	O
300âÂ	300ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
,	,	,	O
300âMHz	300âmhz	CD	O
Î	Î	NNP	O
´	´	CD	O
:	:	:	O
7.06â7.15	7.06â7.15	CD	O

,	,	,	O
11.92	11.92	CD	O
s	s	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
âCONHâ	âCONHâ	NNP	O
.	.	.	O

A	a	DT	O
solution	solution	NN	O
of	of	IN	O
compound	compound	NN	O
2	2	CD	O
5.0âg	5.0âg	CD	O
,	,	,	O
46âmmol	46âmmol	CD	O
in	in	IN	O
hydrazine	hydrazine	NNP	O
hydrate	hydrate	NN	O
100âml	100âml	CD	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
2âh	2âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
cooled	cool	VBN	O
and	and	CC	O
then	then	RB	O
filtered	filter	VBN	O
to	to	TO	O
obtain	obtain	VB	O
3-hydrazinylquinoxalin-2-one	3-hydrazinylquinoxalin-2-one	CD	O
as	as	IN	O
a	a	DT	O
yellow	yellow	JJ	O
solid	solid	JJ	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
84	84	CD	O
%	%	NN	O
,	,	,	O
m.p	m.p	NNP	O
.	.	NNP	O

>	>	XX	O
300âÂ	300ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
,	,	,	O
300âMHz	300âmhz	CD	O
Î	Î	NNP	O
´	´	CD	O
:	:	:	O
4.52	4.52	CD	O
,	,	,	O
7.11â7.37	7.11â7.37	CD	O
,	,	,	O
8.37	8.37	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNS	O
,	,	,	O
âNHâ	âNHâ	NNS	O
,	,	,	O
12.07	12.07	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
âCONHâ	âCONHâ	NNP	O
.	.	.	O

To	to	IN	O
a	a	DT	O
suspension	suspension	NN	O
of	of	IN	O
compound	compound	NN	O
3	3	CD	O
1.3âg	1.3âg	CD	O
,	,	,	O
5âmmol	5âmmol	CD	O
in	in	IN	O
diethyl	diethyl	NNP	O
oxalate	oxalate	NN	O
15âml	15âml	CD	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
reflux	reflux	NN	O
for	for	IN	O
3âh	3âh	CD	O
.	.	.	O

The	the	DT	O
solvent	solvent	NN	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
to	to	TO	O
give	give	VB	O
light	light	JJ	O
yellow	yellow	JJ	O
oil	oil	NN	O
.	.	.	O

The	the	DT	O
crude	crude	JJ	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
column	column	NN	O
chromatography	chromatography	NN	O
and	and	CC	O
recrystallized	recrystallize	VBN	O
from	from	IN	O
petroleum	petroleum	NN	O
ether	ether	NN	O
to	to	TO	O
give	give	VB	O
compound	compound	NN	O
4	4	CD	O
,	,	,	O
yield	yield	VB	O
:	:	:	O
34	34	CD	O
%	%	NN	O
.	.	.	O

A	a	DT	O
mixture	mixture	NN	O
of	of	IN	O
compound	compound	NN	O
4	4	CD	O
0.52âg	0.52âg	CD	O
,	,	,	O
2âmmol	2âmmol	CD	O
,	,	,	O
K2CO3	K2CO3	NNP	O

0.28âg	0.28âg	CD	O
,	,	,	O
2âmmol	2âmmol	CD	O
and	and	CC	O
all	all	DT	O
kinds	kind	NNS	O
of	of	IN	O
halogenated	halogenate	VBN	O
alkanes	alkane	NNS	O
2.4âmmol	2.4âmmol	CD	O
in	in	IN	O
DMF	DMF	NNP	O
25âml	25âml	CD	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
50âÂ	50âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
for	for	IN	O
3â5âh	3â5âh	CD	O
monitored	monitor	VBN	O
by	by	IN	O
TLC	TLC	NNP	O
and	and	CC	O
then	then	RB	O
concentrated	concentrate	VBD	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
added	add	VBN	O
water	water	NN	O
50.0âml	50.0âml	NNP	O
and	and	CC	O
extracted	extract	VBN	O
with	with	IN	O
dichloromethane	dichloromethane	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
saturated	saturate	VBN	O
NaCl	NaCl	NNP	O
and	and	CC	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
Na2SO4	Na2SO4	NNP	O
.	.	.	O

Then	then	RB	O
it	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
purified	purify	VBN	O
by	by	IN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NN	O
eluting	elute	VBG	O
with	with	IN	O
a	a	DT	O
gradient	gradient	NN	O
of	of	IN	O
methanol	methanol	NN	O
/	/	SYM	O
dichloromethane	dichloromethane	NN	O
to	to	TO	O
obtain	obtain	VB	O
the	the	DT	O
compounds	compound	NNS	O
5aâ5	5aâ5	XX	O
t	t	NN	O
as	as	IN	O
white	white	JJ	O
solids	solid	NNS	O
.	.	.	O

Yield	yield	NN	O
:	:	:	O
58.9	58.9	CD	O
%	%	NN	O
,	,	,	O
m.p	m.p	NNP	O
.	.	NNP	O

157â159âÂ	157â159ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
CDCl3	CDCl3	NNP	O
,	,	,	O
300âMHz	300âmhz	LS	O
Î	Î	NNP	O
´	´	CD	O
:	:	:	O
1.57	1.57	CD	O
t	t	NN	O
,	,	,	O
3H	3h	NN	O
,	,	,	O
Jâ=â7.1âHz	jâ=â7.1âhz	NN	O
,	,	,	O
âCH3	âch3	CD	O
,	,	,	O
4.67	4.67	CD	O

q	q	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
Jâ=â7.1âHz	jâ=â7.1âhz	NN	O
,	,	,	O
âOâCH2âC	âOâCH2âC	NNP	O
,	,	,	O
5.63	5.63	CD	O
s	s	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
âCH2â	âCH2â	NNP	O
,	,	,	O
7.32â7.46	7.32â7.46	CD	O
,	,	,	O
8.61	8.61	CD	O
d	d	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
Jâ=â8.3âHz	Jâ=â8.3âHz	NNP	O
,	,	,	O
Ar	Ar	NNP	O
-	-	HYPH	O
H	H	NNP	O
.	.	.	O

To	to	IN	O
a	a	DT	O
stirred	stir	VBN	O
solution	solution	NN	O
of	of	IN	O
compound	compound	NN	O
5aâ5	5aâ5	NNP	O
t	t	NN	O
in	in	IN	O
MeOH	MeOH	NNP	O
10âml	10âml	CD	O
and	and	CC	O
ammonium	ammonium	NN	O
hydroxide	hydroxide	NN	O
10âml	10âml	CD	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
2âh	2âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
filtered	filter	VBN	O
and	and	CC	O
then	then	RB	O
washed	wash	VBD	O
with	with	IN	O
MeOH	MeOH	NNP	O
to	to	TO	O
give	give	VB	O
crude	crude	JJ	O
product	product	NN	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
solid	solid	JJ	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
give	give	VB	O
compounds	compound	NNS	O
6aâ6	6aâ6	NNP	O
t	t	NN	O
as	as	IN	O
pale	pale	JJ	O
white	white	JJ	O
solids	solid	NNS	O
.	.	.	O

The	the	DT	O
RAW	RAW	NNP	O
264.7	264.7	CD	O
mouse	mouse	NN	O
macrophage	macrophage	NN	O
cell	cell	NN	O
line	line	NN	O
was	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
China	China	NNP	O
Cell	Cell	NNP	O
Line	Line	NNP	O
Bank	Bank	NNP	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
complete	complete	JJ	O
medium	medium	NN	O
DMEM	DMEM	NNS	O
supplemented	supplement	VBN	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
heat	heat	NN	O
-	-	HYPH	O
inactivated	inactivate	VBN	O
FBS	FBS	NNP	O
,	,	,	O
3âmM	3âmm	CD	O
glutamine	glutamine	NN	O
and	and	CC	O
antibiotics	antibiotic	NNS	O
100âU	100âU	NNP	O
/	/	SYM	O
mL	mL	NNP	O
penicillin	penicillin	NNP	O
and	and	CC	O
100âU	100âu	CD	O
/	/	SYM	O
mL	mL	NNP	O
streptomycin	streptomycin	NNP	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
a	a	DT	O
humidified	humidified	JJ	O
incubator	incubator	NN	O
containing	contain	VBG	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
and	and	CC	O
95	95	CD	O
%	%	NN	O
air	air	NN	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
various	various	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
synthesised	synthesise	VBN	O
compounds	compound	NNS	O
for	for	IN	O
30âmin	30âmin	NNP	O
followed	follow	VBN	O
by	by	IN	O
stimulation	stimulation	NN	O
with	with	IN	O
LPS	LPS	NNP	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
L	L	NNP	O
.	.	.	O

Cell	cell	NN	O
viability	viability	NN	O
studies	study	NNS	O
induced	induce	VBN	O
by	by	IN	O
synthesised	synthesise	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
by	by	IN	O
3	3	CD	O
-	-	HYPH	O
-2,5-diphenyltetrazolium	-2,5-diphenyltetrazolium	NNP	O
bromide	bromide	NN	O
assay	assay	NN	O
.	.	.	O

RAW264.7	RAW264.7	NNP	O

macrophages	macrophage	NNS	O
were	be	VBD	O
seeded	seed	VBN	O
in	in	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
at	at	IN	O
a	a	DT	O
density	density	NN	O
of	of	IN	O
5âÃâ105	5âãâ105	CD	O
cells	cell	NNS	O
/	/	SYM	O
mL	ml	NN	O
in	in	IN	O
complete	complete	JJ	O
medium	medium	NN	O
and	and	CC	O
incubated	incubate	VBD	O
for	for	IN	O
24âh	24âh	CD	O
100âÂµL	100ââµl	CD	O
/	/	SYM	O
well	well	UH	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
synthesised	synthesise	VBN	O
compounds	compound	NNS	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

150âÂµL	150ââµl	CD	O
MTT	MTT	NNP	O
5âg	5âg	CD	O
/	/	SYM	O
L	L	NNP	O
in	in	IN	O
PBS	PBS	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
each	each	DT	O
well	well	RB	O
and	and	CC	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
further	further	RB	O
incubated	incubate	VBN	O
for	for	IN	O
4âh	4âh	CD	O
.	.	.	O

The	the	DT	O
supernatant	supernatant	JJ	O
was	be	VBD	O
removed	remove	VBN	O
and	and	CC	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
lysed	lyse	VBN	O
with	with	IN	O
150âÂµL	150ââµl	CD	O
/	/	SYM	O
well	well	NN	O
DMSO	DMSO	NNS	O
.	.	.	O

The	the	DT	O
optical	optical	JJ	O
density	density	NN	O
was	be	VBD	O
measured	measure	VBN	O
at	at	IN	O
570ânm	570ânm	CD	O
on	on	IN	O
a	a	DT	O
microplate	microplate	NN	O
reader	reader	NN	O
.	.	.	O

Nitrite	Nitrite	NNP	O
,	,	,	O
a	a	DT	O
stable	stable	JJ	O
product	product	NN	O
of	of	IN	O
nitric	nitric	JJ	O
oxide	oxide	NN	O
,	,	,	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
assess	assess	VB	O
NO	no	DT	O
production	production	NN	O
.	.	.	O

To	to	TO	O
study	study	VB	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
isolated	isolated	JJ	O
compounds	compound	NNS	O
on	on	IN	O
NO	no	DT	O
production	production	NN	O
,	,	,	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
plated	plate	VBN	O
at	at	IN	O
1âÃâ105	1âãâ105	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	RB	O
in	in	IN	O
a	a	DT	O
96-well	96-well	CD	O
microplate	microplate	NN	O
and	and	CC	O
incubated	incubate	VBD	O
overnight	overnight	RB	O
.	.	.	O

The	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
various	various	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compounds	compound	NNS	O
3	3	CD	O
,	,	,	O
7.5	7.5	CD	O
,	,	,	O
10	10	CD	O
,	,	,	O
15	15	CD	O
,	,	,	O
30	30	CD	O
or	or	CC	O
100âÂµM	100ââµm	CD	O
and	and	CC	O
further	far	RBR	O
co	co	VB	O
-	-	JJ	O
cultured	cultured	JJ	O
with	with	IN	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
LPS	LPS	NNP	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

Un	Un	NNP	O
-	-	HYPH	O
pre	pre	NNP	O
-	-	JJ	O
treated	treat	VBN	O
and	and	CC	O
un	un	NNP	O
-	-	HYPH	O
stimulated	stimulate	VBN	O
RAW	RAW	NNP	O
264.7	264.7	CD	O
cells	cell	NNS	O
were	be	VBD	O
conducted	conduct	VBN	O
as	as	IN	O
the	the	DT	O
blank	blank	JJ	O
control	control	NN	O
group	group	NN	O
.	.	.	O

At	at	IN	O
different	different	JJ	O
time	time	NN	O
points	point	NNS	O
,	,	,	O
the	the	DT	O
supernatant	supernatant	JJ	O
50âÂµL	50ââµl	CD	O
was	be	VBD	O
assayed	assay	VBN	O
with	with	IN	O
NO	no	DT	O
assay	assay	NN	O
kit	kit	NN	O
.	.	.	O

The	the	DT	O
culture	culture	NN	O
supernatant	supernatant	JJ	O
50âÂµL	50ââµl	CD	O
was	be	VBD	O
mixed	mix	VBN	O
with	with	IN	O
an	an	DT	O
equal	equal	JJ	O
volume	volume	NN	O
of	of	IN	O
the	the	DT	O
Griess	griess	JJ	O
reagent	reagent	NN	O
1	1	CD	O
%	%	NN	O
sulphanilamide	sulphanilamide	NN	O
,	,	,	O
0.1	0.1	CD	O
%	%	NN	O
N	n	CD	O
-	-	HYPH	O
ethylenediamine	ethylenediamine	NN	O
dihydrochloride	dihydrochloride	NN	O
and	and	CC	O
NO	no	DT	O
production	production	NN	O
were	be	VBD	O
determined	determine	VBN	O
at	at	IN	O
540ânm	540ânm	CD	O
with	with	IN	O
an	an	DT	O
ELISAplate	elisaplate	NN	O
reader	reader	NN	O
.	.	.	O

RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
seeded	seed	VBN	O
at	at	IN	O
3âÃâ105	3âãâ105	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	RB	O
in	in	IN	O
a	a	DT	O
48-well	48-well	CD	O
microplate	microplate	NN	O
and	and	CC	O
incubated	incubate	VBD	O
overnight	overnight	RB	O
.	.	.	O

The	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
the	the	DT	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compunds	compund	NNS	O
3	3	CD	O
,	,	,	O
7.5	7.5	CD	O
,	,	,	O
10	10	CD	O
or	or	CC	O
30âÂµM	30ââµm	CD	O
for	for	IN	O
30âmin	30âmin	NN	O
before	before	IN	O
the	the	DT	O
stimulation	stimulation	NN	O
with	with	IN	O
LPS	LPS	NNP	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
.	.	.	O

According	accord	VBG	O
to	to	IN	O
the	the	DT	O
protocol	protocol	NN	O
of	of	IN	O
the	the	DT	O
manufacturer	manufacturer	NN	O
,	,	,	O
supernatants	supernatant	NNS	O
were	be	VBD	O
harvested	harvest	VBN	O
at	at	IN	O
the	the	DT	O
24th	24th	JJ	O
hour	hour	NN	O
for	for	IN	O
the	the	DT	O
assay	assay	NN	O
of	of	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
or	or	CC	O
IL-6	il-6	JJ	O
with	with	IN	O
ELISA	ELISA	NNP	O
kits	kit	NNS	O
.	.	.	O

Briefly	briefly	RB	O
,	,	,	O
100âÂµL	100ââµl	CD	O
of	of	IN	O
biotinylated	biotinylate	VBN	O
antibody	antibody	NN	O
reagent	reagent	NN	O
and	and	CC	O
the	the	DT	O
culture	culture	NN	O
supernatants	supernatant	NNS	O
were	be	VBD	O
added	add	VBN	O
to	to	IN	O
anti	anti	JJ	O
-	-	JJ	O
mouse	mouse	JJ	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
or	or	CC	O
IL-6	il-6	NN	O
precoated	precoate	VBD	O
96-well	96-well	CD	O
plates	plate	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
plates	plate	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
for	for	IN	O
2âh	2âh	CD	O
at	at	IN	O
RT	RT	NNP	O
.	.	.	O

The	the	DT	O
plate	plate	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
a	a	DT	O
washing	washing	JJ	O
buffer	buffer	NN	O
and	and	CC	O
subsequently	subsequently	RB	O
incubated	incubate	VBD	O
with	with	IN	O
100âÂµL	100ââµl	CD	O
of	of	IN	O
the	the	DT	O
streptavidin	streptavidin	NNP	O
-	-	HYPH	O
HRP	HRP	NNP	O
solution	solution	NN	O
for	for	IN	O
1âh	1âh	CD	O
at	at	IN	O
RT	RT	NNP	O
.	.	.	O

The	the	DT	O
plate	plate	NN	O
was	be	VBD	O
washed	wash	VBN	O
,	,	,	O
and	and	CC	O
incubated	incubate	VBD	O
with	with	IN	O
100âÂµL	100ââµl	CD	O
of	of	IN	O
TMB	TMB	NNP	O
substrate	substrate	NN	O
solution	solution	NN	O
for	for	IN	O
30âmin	30âmin	NN	O
at	at	IN	O
RT	RT	NNP	O
in	in	IN	O
the	the	DT	O
dark	dark	NN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
stopped	stop	VBN	O
by	by	IN	O
adding	add	VBG	O
50âÂµL	50ââµl	CD	O
of	of	IN	O
stop	stop	NN	O
solution	solution	NN	O
,	,	,	O
and	and	CC	O
then	then	RB	O
the	the	DT	O
absorbance	absorbance	NN	O
was	be	VBD	O
measured	measure	VBN	O
at	at	IN	O
450ânm	450ânm	CD	O
by	by	IN	O
a	a	DT	O
plate	plate	NN	O
reader	reader	NN	O
.	.	.	O

A	a	DT	O
standard	standard	JJ	O
curve	curve	NN	O
was	be	VBD	O
produced	produce	VBN	O
for	for	IN	O
each	each	DT	O
assay	assay	NNP	O
plate	plate	NN	O
using	use	VBG	O
serially	serially	RB	O
diluted	dilute	VBN	O
recombinant	recombinant	JJ	O
IL-6	il-6	NN	O
.	.	.	O

RAW	raw	JJ	O
264.7	264.7	CD	O
cells	cell	NNS	O
5âÃâ105	5âãâ105	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	RB	O
plated	plate	VBN	O
onto	onto	IN	O
6-well	6-well	CD	O
plates	plate	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
for	for	IN	O
24âh	24âh	CD	O
and	and	CC	O
treated	treat	VBN	O
with	with	IN	O
7.5	7.5	CD	O
,	,	,	O
15.0	15.0	CD	O
or	or	CC	O
30.0âÂµM	30.0ââµm	CD	O
of	of	IN	O
compound	compound	NNP	O
6p	6p	NNP	O
for	for	IN	O
30âmin	30âmin	NN	O
and	and	CC	O
then	then	RB	O
stimulated	stimulate	VBD	O
with	with	IN	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
L	L	NNP	O
of	of	IN	O
LPS	LPS	NNP	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

The	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
collected	collect	VBN	O
and	and	CC	O
washed	wash	VBD	O
three	three	CD	O
times	time	NNS	O
with	with	IN	O
ice	ice	NN	O
-	-	HYPH	O
cold	cold	JJ	O
PBS	PBS	NNP	O
.	.	.	O

The	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
a	a	DT	O
cell	cell	NN	O
lysis	lysis	NN	O
buffer	buffer	NN	O
50âmM	50âmm	CD	O
Tris	Tris	NNP	O
pH	pH	NNP	O
7.6	7.6	CD	O
,	,	,	O
150âmM	150âmm	CD	O
NaCl	NaCl	NNP	O
,	,	,	O
5âmM	5âmm	CD	O
EDTA	edta	NN	O
,	,	,	O
0.6	0.6	CD	O
%	%	NN	O
NP-40	NP-40	NNP	O
,	,	,	O
1âmM	1âmm	CD	O
Na3VO4	na3vo4	NN	O
,	,	,	O
20âmM	20âmm	CD	O
Î²-glycerophosphate	î²-glycerophosphate	CD	O
,	,	,	O
1âmM	1âmm	CD	O
phenylmethylsulfonyl	phenylmethylsulfonyl	NN	O
fluoride	fluoride	NN	O
,	,	,	O
2âmM	2âmm	CD	O
p	p	NN	O
-	-	HYPH	O
nitrophenyl	nitrophenyl	NN	O
phosphate	phosphate	NN	O
,	,	,	O
and	and	CC	O
1:25	1:25	CD	O
Complete	complete	JJ	O
Mini	Mini	NNP	O
Protease	Protease	NNP	O
Inhibitor	Inhibitor	NNP	O
cocktail	cocktail	NN	O
Boehringer	Boehringer	NNP	O
,	,	,	O
Mannheim	Mannheim	NNP	O
,	,	,	O
Germany	Germany	NNP	O
and	and	CC	O
kept	keep	VBD	O
on	on	IN	O
ice	ice	NN	O
for	for	IN	O
30âmin	30âmin	NN	O
.	.	.	O

The	the	DT	O
cell	cell	NN	O
lysates	lysate	NNS	O
were	be	VBD	O
centrifuged	centrifuge	VBN	O
12,000âg	12,000âg	CD	O
at	at	IN	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
5âmin	5âmin	CD	O
to	to	TO	O
obtain	obtain	VB	O
a	a	DT	O
cytosolic	cytosolic	JJ	O
fraction	fraction	NN	O
.	.	.	O

The	the	DT	O
protein	protein	NN	O
concentration	concentration	NN	O
was	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
BCA	BCA	NNP	O
protein	protein	NN	O
assay	assay	NN	O
kit	kit	NN	O
.	.	.	O

Aliquots	aliquot	NNS	O
of	of	IN	O
the	the	DT	O
lysates	lysate	NNS	O
were	be	VBD	O
separated	separate	VBN	O
on	on	IN	O
10	10	CD	O
%	%	NN	O
sodium	sodium	NN	O
dodecyl	dodecyl	VBN	O
sulphate	sulphate	NN	O
-polyacrylamide	-polyacrylamide	HYPH	O
gel	gel	NN	O
electrophoresis	electrophoresis	NN	O
and	and	CC	O
then	then	RB	O
electro	electro	NNP	O
blotted	blot	VBD	O
onto	onto	IN	O
a	a	DT	O
polyvinylidene	polyvinylidene	JJ	O
difluoride	difluoride	NN	O
membrane	membrane	NN	O
.	.	.	O

The	the	DT	O
blots	blot	NNS	O
were	be	VBD	O
blocked	block	VBN	O
with	with	IN	O
5	5	CD	O
%	%	NN	O
non	non	JJ	O
-	-	JJ	O
fat	fat	JJ	O
dry	dry	JJ	O
milk	milk	NN	O
for	for	IN	O
2âh	2âh	CD	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
incubation	incubation	NN	O
with	with	IN	O
specific	specific	JJ	O
primary	primary	JJ	O
antibody	antibody	NN	O
at	at	IN	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
overnight	overnight	RB	O
.	.	.	O

Blots	blot	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
Tween	Tween	NNP	O
20	20	CD	O
/	/	SYM	O
Tris	Tris	NNP	O
-	-	HYPH	O
buffered	buffer	VBN	O
saline	saline	NN	O
TTBS	TTBS	NNP	O
,	,	,	O
20âmM	20âmm	CD	O
TrisâHCl	TrisâHCl	NNP	O
buffer	buffer	NN	O
,	,	,	O
pH	pH	NNP	O
7.6	7.6	CD	O
,	,	,	O
containing	contain	VBG	O
137âmM	137âmm	CD	O
NaCl	NaCl	NNP	O
and	and	CC	O
0.05	0.05	CD	O
%	%	NN	O
Tween	Tween	NNP	O
20	20	CD	O
and	and	CC	O
incubated	incubate	VBN	O
with	with	IN	O
a	a	DT	O
peroxidase	peroxidase	NN	O
-	-	HYPH	O
conjugated	conjugate	VBN	O
secondary	secondary	JJ	O
antibody	antibody	NN	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

Blots	blot	NNS	O
were	be	VBD	O
again	again	RB	O
washed	wash	VBN	O
with	with	IN	O
TTBS	TTBS	NNP	O
and	and	CC	O
the	the	DT	O
immune	immune	JJ	O
active	active	JJ	O
proteins	protein	NNS	O
were	be	VBD	O
detected	detect	VBN	O
using	use	VBG	O
ECL	ECL	NNP	O
plus	plus	CC	O
.	.	.	O

All	all	DT	O
Western	western	JJ	O
blot	blot	NN	O
analyses	analysis	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
times	time	NNS	O
.	.	.	O

Results	result	NNS	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
the	the	DT	O
relative	relative	JJ	O
ratio	ratio	NN	O
of	of	IN	O
the	the	DT	O
specific	specific	JJ	O
band	band	NN	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
internal	internal	JJ	O
reference	reference	NN	O
.	.	.	O

The	the	DT	O
animal	animal	NN	O
procedures	procedure	NNS	O
were	be	VBD	O
in	in	IN	O
strict	strict	JJ	O
accordance	accordance	NN	O
with	with	IN	O
the	the	DT	O
National	National	NNP	O
Institutes	Institutes	NNPS	O
of	of	IN	O
Healthy	Healthy	NNP	O
Guidelines	Guidelines	NNPS	O
for	for	IN	O
the	the	DT	O
Care	Care	NNP	O
and	and	CC	O
Use	Use	NNP	O
of	of	IN	O
Laboratory	Laboratory	NNP	O
Animals	Animals	NNPS	O
NIH	NIH	NNP	O
Publication	Publication	NNP	O
No	no	NN	O
.	.	NN	O

85	85	CD	O
-	-	SYM	O
23	23	CD	O
,	,	,	O
revised	revise	VBN	O
1996	1996	CD	O
and	and	CC	O
were	be	VBD	O
approved	approve	VBN	O
by	by	IN	O
the	the	DT	O
Institutional	Institutional	NNP	O
Animal	Animal	NNP	O
Care	Care	NNP	O
and	and	CC	O
Utilisation	Utilisation	NNP	O
Committee	Committee	NNP	O
of	of	IN	O
Yanbian	Yanbian	NNP	O
University	University	NNP	O
.	.	.	O

Male	Male	NNP	O
albino	albino	NN	O
rats	rat	VBZ	O
weighing	weigh	VBG	O
280â300	280â300	CD	O
gwere	gwere	RB	O
obtained	obtain	VBN	O
from	from	IN	O
Animal	Animal	NNP	O
Department	Department	NNP	O
of	of	IN	O
Yanbian	Yanbian	NNP	O
University	University	NNP	O
.	.	.	O

They	-PRON-	PRP	O
were	be	VBD	O
kept	keep	VBN	O
in	in	IN	O
the	the	DT	O
animal	animal	NN	O
house	house	NN	O
under	under	IN	O
standard	standard	JJ	O
condition	condition	NN	O
of	of	IN	O
light	light	NN	O
and	and	CC	O
temperature	temperature	NN	O
with	with	IN	O
free	free	JJ	O
access	access	NN	O
to	to	IN	O
food	food	NN	O
and	and	CC	O
water	water	NN	O
.	.	.	O

The	the	DT	O
animals	animal	NNS	O
were	be	VBD	O
randomly	randomly	RB	O
divided	divide	VBN	O
into	into	IN	O
five	five	CD	O
groups	group	NNS	O
control	control	NN	O
,	,	,	O
D1	d1	NN	O
,	,	,	O
6p	6p	NN	O
,	,	,	O
ibuprofen	ibuprofen	NNP	O
and	and	CC	O
celecoxib	celecoxib	JJ	O
group	group	NN	O
The	the	DT	O
groups	group	NNS	O
with	with	IN	O
D1	d1	NN	O
,	,	,	O
6p	6p	CD	O
,	,	,	O
ibuprofen	ibuprofen	NNP	O
and	and	CC	O
celecoxib	celecoxib	NNP	O
were	be	VBD	O
administered	administer	VBN	O
oral	oral	JJ	O
administration	administration	NNP	O
25âmg	25âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
in	in	IN	O
a	a	DT	O
vehicle	vehicle	NN	O
of	of	IN	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose	methylcellulose	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
negative	negative	JJ	O
control	control	NN	O
group	group	NN	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
the	the	DT	O
same	same	JJ	O
vehicle	vehicle	NN	O
.	.	.	O

A	a	DT	O
solution	solution	NN	O
of	of	IN	O
carrageenan	carrageenan	NNP	O
0.1âml	0.1âml	NNP	O
,	,	,	O
1.0	1.0	CD	O
%	%	NN	O
w	w	NN	O
/	/	SYM	O
v	v	NN	O
in	in	IN	O
0.9	0.9	CD	O
%	%	NN	O
of	of	IN	O
normal	normal	JJ	O
saline	saline	NN	O
was	be	VBD	O
injected	inject	VBN	O
into	into	IN	O
the	the	DT	O
subplanter	subplanter	NN	O
region	region	NN	O
of	of	IN	O
the	the	DT	O
left	left	JJ	O
hind	hind	NN	O
paw	paw	NN	O
under	under	IN	O
light	light	JJ	O
ether	ether	NN	O
anaesthesia	anaesthesia	NNP	O
1âh	1âh	CD	O
after	after	IN	O
oral	oral	NNP	O
administration	administration	NN	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compound	compound	NN	O
at	at	IN	O
a	a	DT	O
dose	dose	JJ	O
level	level	NN	O
of	of	IN	O
25âmg	25âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
body	body	NN	O
weight	weight	NN	O
.	.	.	O

The	the	DT	O
paw	paw	NN	O
volume	volume	NN	O
was	be	VBD	O
measured	measure	VBN	O
at	at	IN	O
hourly	hourly	NNP	O
interval	interval	NN	O
for	for	IN	O
5âh	5âh	CD	O
0	0	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
3	3	CD	O
and	and	CC	O
5âh	5âh	CD	O
and	and	CC	O
the	the	DT	O
percent	percent	NN	O
inhibition	inhibition	NN	O
of	of	IN	O
oedema	oedema	NNP	O
was	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
formula	formula	NN	O
:	:	:	O
%	%	NN	O
Inhibition=(VtâVo)controlâ(VtâVo)testedÂ	Inhibition=(VtâVo)controlâ(VtâVo)testedÂ	NNP	O
compoundâ/(VtâVo)controlÃ100	compoundâ/(VtâVo)controlÃ100	NNS	O

where	where	WRB	O
,	,	,	O
Voâ=âvolume	Voâ=âvolume	NNP	O
of	of	IN	O
oedema	oedema	NNP	O
at	at	IN	O
zero	zero	CD	O
time	time	NN	O
interval	interval	NN	O
.	.	.	O

Vtâ=âvolume	Vtâ=âvolume	NNP	O
of	of	IN	O
oedema	oedema	NNP	O
at	at	IN	O
specific	specific	JJ	O
time	time	NN	O
interval	interval	NN	O
.	.	.	O

Voâ=âvolume	Voâ=âvolume	NNP	O
of	of	IN	O
oedema	oedema	NNP	O
at	at	IN	O
zero	zero	CD	O
time	time	NN	O
interval	interval	NN	O
.	.	.	O

Vtâ=âvolume	Vtâ=âvolume	NNP	O
of	of	IN	O
oedema	oedema	NNP	O
at	at	IN	O
specific	specific	JJ	O
time	time	NN	O
interval	interval	NN	O
.	.	.	O

The	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
D1	d1	NN	O
and	and	CC	O
the	the	DT	O
newly	newly	RB	O
synthesised	synthesise	VBN	O
compound	compound	NN	O
6p	6p	CD	O
were	be	VBD	O
subjected	subject	VBN	O
to	to	IN	O
in	in	IN	O
vivo	vivo	NNP	O
testing	testing	NN	O
to	to	TO	O
measure	measure	VB	O
their	-PRON-	PRP$	O
ulcerogenic	ulcerogenic	JJ	O
effect	effect	NN	O
in	in	IN	O
comparison	comparison	NN	O
to	to	TO	O
celecoxib	celecoxib	VB	O
and	and	CC	O
ibuprofen	ibuprofen	JJ	O
.	.	.	O

Male	male	JJ	O
albino	albino	NNP	O
rats	rat	NNS	O
220â250âg	220â250âg	CD	O
divided	divide	VBD	O
into	into	IN	O
5	5	CD	O
groups	group	NNS	O
of	of	IN	O
five	five	CD	O
rats	rat	NNS	O
each	each	DT	O
.	.	.	O

The	the	DT	O
groups	group	NNS	O
with	with	IN	O
D1	d1	NN	O
,	,	,	O
6p	6p	CD	O
,	,	,	O
ibuprofen	ibuprofen	NN	O
,	,	,	O
and	and	CC	O
celecoxib	celecoxib	NNP	O
were	be	VBD	O
administered	administer	VBN	O
oral	oral	JJ	O
administration	administration	NNP	O
25âmg	25âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
in	in	IN	O
a	a	DT	O
vehicle	vehicle	NN	O
of	of	IN	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose	methylcellulose	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
negative	negative	JJ	O
control	control	NN	O
group	group	NN	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
the	the	DT	O
same	same	JJ	O
vehicle	vehicle	NN	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose	methylcellulose	NN	O
.	.	.	O

All	all	DT	O
groups	group	NNS	O
were	be	VBD	O
orally	orally	RB	O
administered	administer	VBN	O
once	once	RB	O
a	a	DT	O
day	day	NN	O
for	for	IN	O
three	three	CD	O
consecutive	consecutive	JJ	O
days	day	NNS	O
.	.	.	O

Animals	animal	NNS	O
were	be	VBD	O
sacrificed	sacrifice	VBN	O
by	by	IN	O
diethyl	diethyl	NN	O
ether	ether	NN	O
6âh	6âh	CD	O
after	after	IN	O
the	the	DT	O
last	last	JJ	O
dose	dose	NN	O
and	and	CC	O
the	the	DT	O
stomach	stomach	NN	O
was	be	VBD	O
removed	remove	VBN	O
.	.	.	O

An	an	DT	O
opening	opening	NN	O
at	at	IN	O
the	the	DT	O
greater	great	JJR	O
curvature	curvature	NN	O
was	be	VBD	O
made	make	VBN	O
and	and	CC	O
the	the	DT	O
stomach	stomach	NN	O
was	be	VBD	O
cleaned	clean	VBN	O
by	by	IN	O
washing	wash	VBG	O
with	with	IN	O
cold	cold	JJ	O
saline	saline	NN	O
and	and	CC	O
inspected	inspect	VBN	O
with	with	IN	O
a	a	DT	O
three	three	CD	O
-	-	HYPH	O
time	time	NN	O
magnifying	magnify	VBG	O
lens	lens	NN	O
for	for	IN	O
any	any	DT	O
evidence	evidence	NN	O
of	of	IN	O
hyperaemia	hyperaemia	NN	O
,	,	,	O
haemorrhage	haemorrhage	NN	O
,	,	,	O
definite	definite	JJ	O
haemorrhagic	haemorrhagic	JJ	O
erosion	erosion	NN	O
,	,	,	O
or	or	CC	O
ulcer	ulcer	NN	O
.	.	.	O

An	an	DT	O
arbitrary	arbitrary	JJ	O
scale	scale	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
calculate	calculate	VB	O
the	the	DT	O
ulcer	ulcer	NN	O
index	index	NN	O
which	which	WDT	O
indicates	indicate	VBZ	O
the	the	DT	O
severity	severity	NN	O
of	of	IN	O
the	the	DT	O
stomach	stomach	NN	O
lesions	lesion	VBZ	O
The	the	DT	O
%	%	NN	O
ulceration	ulceration	NN	O
for	for	IN	O
each	each	DT	O
group	group	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
as	as	IN	O
follows	follow	VBZ	O
:	:	:	O
%	%	NN	O
Ulcerationâ=âNumber	ulcerationâ=ânumber	CD	O
of	of	IN	O
animals	animal	NNS	O
bearing	bear	VBG	O
ulcer	ulcer	NN	O
in	in	IN	O
a	a	DT	O
group	group	NN	O
/	/	SYM	O
Total	total	JJ	O
number	number	NN	O
of	of	IN	O
animals	animal	NNS	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
group	group	NN	O
Ã100	Ã100	VBZ	O
.	.	.	O

The	the	DT	O
steps	step	NNS	O
involved	involve	VBN	O
in	in	IN	O
the	the	DT	O
preparation	preparation	NN	O
of	of	IN	O
the	the	DT	O
target	target	NN	O
compounds	compound	VBZ	O
6aâ6	6aâ6	NNP	O
t	t	NNP	O
are	be	VBP	O
outlined	outline	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
1	1	CD	O
.	.	.	O

The	the	DT	O
starting	starting	NN	O
material	material	NN	O
,	,	,	O
o	o	NN	O
-	-	HYPH	O
phenylenediamine	phenylenediamine	NN	O
,	,	,	O
was	be	VBD	O
reacted	react	VBN	O
with	with	IN	O
oxalic	oxalic	JJ	O
acid	acid	NN	O
in	in	IN	O
10	10	CD	O
%	%	NN	O
hydrochloric	hydrochloric	JJ	O
acid	acid	NN	O
to	to	TO	O
obtain	obtain	VB	O
quinoxaline-2,3-dione	quinoxaline-2,3-dione	NNP	O
a	a	DT	O
white	white	JJ	O
needle	needle	NN	O
solid	solid	JJ	O
.	.	.	O

Unlike	unlike	IN	O
in	in	IN	O
the	the	DT	O
previous	previous	JJ	O
synthesis	synthesis	NN	O
method	method	NN	B
,	,	,	O
diethyl	diethyl	NN	O
oxalate	oxalate	NN	O
was	be	VBD	O
replaced	replace	VBN	O
with	with	IN	O
hydrochloric	hydrochloric	JJ	O
acid	acid	NN	O
solution	solution	NN	O
in	in	IN	O
oxalic	oxalic	JJ	O
acid	acid	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
white	white	NNP	O
needle	needle	NNP	O
-	-	HYPH	O
like	like	UH	O
solid	solid	JJ	O
was	be	VBD	O
directly	directly	RB	O
precipitated	precipitate	VBN	O
after	after	IN	O
the	the	DT	O
reaction	reaction	NN	O
,	,	,	O
which	which	WDT	O
not	not	RB	O
only	only	RB	O
shortened	shorten	VBD	O
the	the	DT	O
reaction	reaction	NN	O
time	time	NN	O
but	but	CC	O
also	also	RB	O
made	make	VBD	O
the	the	DT	O
post	post	JJ	O
-	-	JJ	O
treatment	treatment	JJ	O
easier	easy	JJR	O
.	.	.	O

Compound	Compound	NNP	O
2	2	CD	O
was	be	VBD	O
then	then	RB	O
reacted	react	VBN	O
with	with	IN	O
hydrazine	hydrazine	NN	O
hydrate	hydrate	NN	O
to	to	TO	O
obtain	obtain	VB	O
compound	compound	NN	O
3	3	CD	O
3-hydrazinylquinoxalin-2-one	3-hydrazinylquinoxalin-2-one	CD	O
with	with	IN	O
only	only	RB	O
one	one	CD	O
carbonyl	carbonyl	NN	O
group	group	NN	O
substituted	substitute	VBN	B
,	,	,	O
and	and	CC	O
compound	compound	NNP	O
4	4	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
by	by	IN	O
cyclizing	cyclize	VBG	O
compound	compound	NN	O
3	3	CD	O
with	with	IN	O
diethyl	diethyl	NN	O
oxalate	oxalate	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
compound	compound	NN	O
4	4	CD	O
was	be	VBD	O
reacted	react	VBN	O
with	with	IN	O
appropriate	appropriate	JJ	O
brominated	brominated	JJ	O
alkanes	alkane	NNS	O
and	and	CC	O
substituted	substitute	VBN	O
with	with	IN	O
chlorobenzyl	chlorobenzyl	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
K2CO3	K2CO3	NNP	O
to	to	TO	O
yield	yield	VB	O
compounds	compound	NNS	O
5aâ5	5aâ5	XX	O
t	t	NN	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
reacted	react	VBN	O
further	further	RB	O
with	with	IN	O
NH3Â·H2O	NH3Â·H2O	NNP	O
in	in	IN	O
methanol	methanol	NN	O
to	to	TO	O
obtain	obtain	VB	O
the	the	DT	O
target	target	NN	O
compounds	compound	VBZ	O
6aâ6	6aâ6	NNP	O
t	t	NN	B
.	.	.	O

The	the	DT	O
synthesised	synthesise	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
by	by	IN	O
1H	1h	JJ	O
-	-	HYPH	O
NMR	NMR	NNP	O
,	,	,	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
,	,	,	O
and	and	CC	O
HRMS	HRMS	NNP	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
oxalic	oxalic	JJ	O
acid	acid	NN	O
,	,	,	O
HCl	HCl	NNP	O
/	/	SYM	O
H2O	h2o	NN	O
,	,	,	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
2âh	2âh	CD	O
;	;	:	O
Hydrazine	Hydrazine	NNP	O
hydrate	hydrate	NN	O
,	,	,	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
2âh	2âh	CD	O
;	;	:	O
Diethyl	Diethyl	NNP	O
oxalate	oxalate	NN	O
,	,	,	O
reflux	reflux	NN	O
,	,	,	O
3âh	3âh	CD	O
;	;	:	O
RX	RX	NNP	O
,	,	,	O
K2CO3	K2CO3	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
60âÂ	60ââ	RB	O
°	°	NNP	O
C	C	NNP	O
,	,	,	O
3âh	3âh	CD	O
;	;	:	O
NH3Â·H2O	nh3â·h2o	UH	O
,	,	,	O
methanol	methanol	NN	O
,	,	,	O
r.t	r.t	NNP	O
.	.	NNP	O

,	,	,	O
2âh	2âh	CD	O
.	.	.	O

To	to	TO	O
investigate	investigate	VB	O
whether	whether	IN	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activities	activity	NNS	O
of	of	IN	O
the	the	DT	O
target	target	NN	O
compounds	compound	VBZ	O
6aâ6	6aâ6	NNP	O
t	t	NNP	O
were	be	VBD	O
related	relate	VBN	O
to	to	IN	O
cell	cell	NN	O
viability	viability	NN	O
,	,	,	O
their	-PRON-	PRP$	O
cytotoxic	cytotoxic	JJ	O
effects	effect	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
by	by	IN	O
MTT	MTT	NNP	O
assay	assay	NNP	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	B
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
,	,	,	O
except	except	IN	O
for	for	IN	O
compounds	compound	NNS	O
6i	6i	NNP	O
and	and	CC	O
6j	6j	NNP	O
,	,	,	O
the	the	DT	O
other	other	JJ	O
compounds	compound	NNS	O
at	at	IN	O
concentrations	concentration	NNS	O
of	of	IN	O
10	10	CD	O
or	or	CC	O
30âÂµM	30ââµm	CD	O
showed	show	VBD	O
no	no	DT	O
obvious	obvious	JJ	O
cytotoxic	cytotoxic	JJ	O
effects	effect	NNS	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
relative	relative	JJ	O
cell	cell	NN	O
viabilities	viability	NNS	O
of	of	IN	O
the	the	DT	O
treated	treat	VBN	O
cells	cell	NNS	O
were	be	VBD	O
more	more	JJR	O
than	than	IN	O
80	80	CD	O
%	%	NN	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
10âÂµM	10ââµm	CD	O
concentration	concentration	NN	O
was	be	VBD	O
chosen	choose	VBN	O
for	for	IN	O
subsequent	subsequent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

Effect	effect	NN	O
of	of	IN	O
compounds	compound	NNS	O
6aâ6	6aâ6	NNP	O
t	t	NN	O
on	on	IN	O
the	the	DT	O
viability	viability	NN	O
of	of	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
.	.	.	O

LPS	LPS	NNP	O
1âÎ¼g	1âÎ¼g	NNP	O
/	/	SYM	O
mL	ml	NN	O
.	.	.	O

No	no	DT	O
tested	test	VBN	O
.	.	.	O

High	high	JJ	O
levels	level	NNS	O
of	of	IN	O
NO	no	DT	O
are	be	VBP	O
produced	produce	VBN	O
in	in	IN	O
response	response	NN	O
to	to	IN	O
LPS	LPS	NNP	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
in	in	IN	O
the	the	DT	O
activated	activate	VBN	O
RAW264.7	raw264.7	NN	O

macrophages	macrophage	VBZ	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
NO	no	DT	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
been	be	VBN	O
identified	identify	VBN	O
as	as	IN	O
good	good	JJ	O
options	option	NNS	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
diseases	disease	NNS	B
.	.	.	O

The	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activities	activity	NNS	O
of	of	IN	O
the	the	DT	O
target	target	NN	O
compounds	compound	VBZ	O
6aâ6	6aâ6	NNP	O
t	t	NNP	O
were	be	VBD	O
tested	test	VBN	O
based	base	VBN	O
on	on	IN	O
their	-PRON-	PRP$	O
ability	ability	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
NO	no	DT	O
production	production	NN	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
macrophages	macrophage	NNS	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
1	1	CD	O
,	,	,	O
LPS	LPS	NNP	O
treatment	treatment	NN	O
caused	cause	VBD	O
a	a	DT	O
significant	significant	JJ	O
increase	increase	NN	O
in	in	IN	O
NO	no	DT	O
release	release	NN	O
compared	compare	VBN	O
to	to	IN	O
that	that	DT	O
in	in	IN	O
untreated	untreated	JJ	O
controls	control	NNS	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
inhibited	inhibit	VBN	O
after	after	IN	O
treatment	treatment	NN	O
with	with	IN	O
the	the	DT	O
synthetic	synthetic	JJ	O
derivatives	derivative	NNS	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
.	.	.	O

Among	among	IN	O
them	-PRON-	PRP	O
,	,	,	O
compounds	compound	VBZ	O
6b	6b	NNP	O
,	,	,	O
6d	6d	NNP	O
,	,	,	O
6e	6e	NNP	O
,	,	,	O
6f	6f	NNPS	O
,	,	,	O
6i	6i	CD	O
,	,	,	O
6j	6j	NNS	O
,	,	,	O
6n	6n	CD	O
,	,	,	O
6o	6o	NNP	O
,	,	,	O
6p	6p	NNP	O
,	,	,	O
6r	6r	NNP	O
,	,	,	O
and	and	CC	O
6s	6s	NN	O
exhibited	exhibit	VBN	O
similar	similar	JJ	O
or	or	CC	O
better	well	JJR	O
NO	no	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
than	than	IN	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
D1	d1	NN	O
.	.	.	O

Compound	Compound	NNP	O
6p	6p	NNP	O
10âÂµM	10ââµm	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
and	and	CC	O
was	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
D1	d1	NN	O
a	a	DT	O
10.31	10.31	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
.	.	.	O

When	when	WRB	O
the	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
compound	compound	NNP	O
6p	6p	CD	O
was	be	VBD	O
reduced	reduce	VBN	O
to	to	IN	O
3âÂµM	3ââµm	CD	O
,	,	,	O
it	-PRON-	PRP	O
was	be	VBD	O
still	still	RB	O
able	able	JJ	O
to	to	TO	O
significantly	significantly	RB	O
inhibit	inhibit	VB	O
NO	no	DT	O
production	production	NN	O
pâ<â.001	pâ<â.001	NNP	O
Figure	figure	NN	O
2	2	CD	O
.	.	.	O

RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	JJ	O
cultured	cultured	JJ	O
for	for	IN	O
24âh	24âh	CD	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
then	then	RB	O
treated	treat	VBN	O
with	with	IN	O
the	the	DT	O
indicated	indicate	VBN	O
concentrations	concentration	NNS	O
of	of	IN	O
compounds	compound	NNS	O
for	for	IN	O
30âmin	30âmin	NNP	O
,	,	,	O
and	and	CC	O
then	then	RB	O
exposed	expose	VBN	O
to	to	IN	O
1âÎ¼g	1âî¼g	CD	O
/	/	SYM	O
mL	mL	NNP	O
LPS	LPS	NNP	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

The	the	DT	O
levels	level	NNS	O
of	of	IN	O
NO	no	UH	O
in	in	IN	O
the	the	DT	O
culture	culture	NN	O
medium	medium	NN	O
were	be	VBD	O
measured	measure	VBN	O
with	with	IN	O
NO	no	DT	O
assay	assay	NN	O
kit	kit	NN	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
10âÎ¼M	10âî¼m	CD	O
compounds	compound	NNS	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
compound	compound	NNP	O
6p	6p	NNS	O
.	.	.	O

NO	no	UH	O
,	,	,	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
and	and	CC	O
IL-6	il-6	JJ	O
levels	level	NNS	O
in	in	IN	O
the	the	DT	O
medium	medium	NN	O
were	be	VBD	O
determined	determine	VBN	O
with	with	IN	O
an	an	DT	O
ELISA	ELISA	NNP	O
kit	kit	NN	O
.	.	.	O

.	.	.	O

#	#	$	O
#	#	$	O
#	#	$	O
pâ<â.01	pâ<â.01	NNP	O
,	,	,	O
vs.	vs.	IN	O
Control	Control	NNP	O
.	.	.	O

*	*	NFP	O
pâ<â.05	pâ<â.05	NNP	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
pâ<â.01	pâ<â.01	NNP	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
*	*	NFP	O
pâ<â.001	pâ<â.001	CD	O
vs.	vs.	IN	O
LPS	LPS	NNP	O
alone	alone	RB	O
.	.	.	O

The	the	DT	O
following	following	JJ	O
structure	structure	NN	O
-	-	HYPH	O
activity	activity	NN	O
relationships	relationship	NNS	O
of	of	IN	O
the	the	DT	O
synthetic	synthetic	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
determined	determine	VBN	O
:	:	:	O
the	the	DT	O
length	length	NN	O
of	of	IN	O
the	the	DT	O
alkyl	alkyl	NN	O
chain	chain	NN	O
appeared	appear	VBD	O
to	to	TO	O
have	have	VB	O
a	a	DT	O
direct	direct	JJ	O
impact	impact	NN	O
on	on	IN	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
5-alkyl	5-alkyl	CD	O
derivatives	derivative	NNS	O
6aâ6f	6aâ6f	CD	O
.	.	.	O

As	as	IN	O
the	the	DT	O
alkyl	alkyl	NN	O
chain	chain	NN	O
length	length	NN	O
of	of	IN	O
the	the	DT	O
derivatives	derivative	NNS	O
6aâ6e	6aâ6e	CD	O
increased	increase	VBD	O
,	,	,	O
their	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activities	activity	NNS	O
increased	increase	VBD	O
,	,	,	O
with	with	IN	O
compound	compound	NN	O
6e	6e	IN	O
being	be	VBG	O
the	the	DT	O
most	most	RBS	O
active	active	JJ	O
.	.	.	O

When	when	WRB	O
the	the	DT	O
length	length	NN	O
of	of	IN	O
the	the	DT	O
linear	linear	JJ	O
alkyl	alkyl	NN	O
group	group	NN	O
reached	reach	VBD	O
9	9	CD	O
carbon	carbon	NN	O
atoms	atom	NNS	O
compound	compound	NNP	O
6f	6f	RB	O
,	,	,	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
began	begin	VBD	O
to	to	TO	O
decrease	decrease	VB	O
.	.	.	O

We	-PRON-	PRP	O
hypothesised	hypothesise	VBD	O
that	that	IN	O
the	the	DT	O
n	n	NNP	O
-	-	HYPH	O
octyl	octyl	RB	O
-	-	HYPH	O
substituted	substitute	VBN	O
compound	compound	NN	O
,	,	,	O
6e	6e	NN	O
,	,	,	O
has	have	VBZ	O
the	the	DT	O
most	most	RBS	O
favourable	favourable	JJ	O
exponential	exponential	JJ	O
partition	partition	NN	O
coefficient	coefficient	NN	O
and	and	CC	O
easily	easily	RB	O
passes	pass	VBZ	O
through	through	IN	O
the	the	DT	O
cell	cell	NN	O
membrane	membrane	NN	O
.	.	.	O

For	for	IN	O
the	the	DT	O
benzyloxy	benzyloxy	NN	O
-	-	HYPH	O
substituted	substitute	VBN	O
derivatives	derivative	NNS	O
6gâ6	6gâ6	NNP	O
t	t	NN	O
,	,	,	O
the	the	DT	O
type	type	NN	O
and	and	CC	O
position	position	NN	O
of	of	IN	O
the	the	DT	O
substituent	substituent	NN	O
on	on	IN	O
the	the	DT	O
benzene	benzene	NN	O
ring	ring	NN	O
had	have	VBD	O
a	a	DT	O
significant	significant	JJ	O
effect	effect	NN	O
on	on	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
activity	activity	NN	O
order	order	NN	O
was	be	VBD	O
3,4,5-OCH3	3,4,5-och3	CD	O
>	>	XX	O
m	m	NNP	O
-	-	HYPH	O
OCH3	OCH3	NNP	O
>	>	NNP	O
p	p	NNP	O
-	-	HYPH	O
OCH3	OCH3	NNP	O
>	>	NNP	O
m	m	NNP	O
-	-	HYPH	O
F	F	NNP	O
>	>	NNP	O
p	p	NNP	O
-	-	HYPH	O
F	F	NNP	O
>	>	NN	O
m	m	NNP	O
-	-	HYPH	O
CF3	CF3	NNP	O
>	>	NNP	O
p	p	JJ	O
-	-	HYPH	O
NO2	NO2	NNP	O
>	>	NN	O
p	p	NN	O
-	-	HYPH	O
CN	CN	NNP	O
,	,	,	O
indicating	indicate	VBG	O
that	that	IN	O
the	the	DT	O
electron	electron	NN	O
-	-	HYPH	O
donating	donate	VBG	O
group	group	NN	O
exerts	exert	VBZ	O
a	a	DT	O
greater	great	JJR	O
effect	effect	NN	O
than	than	IN	O
the	the	DT	O
electron	electron	NN	O
-	-	HYPH	O
withdrawing	withdraw	VBG	O
group	group	NN	O
in	in	IN	O
increasing	increase	VBG	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activities	activity	NNS	O
of	of	IN	O
these	these	DT	O
derivatives	derivative	NNS	O
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
initial	initial	JJ	O
screening	screening	NN	O
results	result	NNS	O
of	of	IN	O
these	these	DT	O
synthetic	synthetic	JJ	O
derivatives	derivative	NNS	O
,	,	,	O
compound	compound	NNP	O
6p	6p	CD	O
was	be	VBD	O
chosen	choose	VBN	O
for	for	IN	O
further	further	JJ	O
assessment	assessment	NN	O
of	of	IN	O
its	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
in	in	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
macrophages	macrophage	NNS	O
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
well	well	RB	O
known	know	VBN	O
that	that	IN	O
the	the	DT	O
pro	pro	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	O
IL-6	il-6	JJ	O
and	and	CC	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	î±	NN	O
play	play	VBP	O
important	important	JJ	O
roles	role	NNS	O
in	in	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
inflammation	inflammation	NN	O
-	-	HYPH	O
related	relate	VBN	O
diseases	disease	NNS	B
.	.	.	O

To	to	TO	O
measure	measure	VB	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
compound	compound	NN	O
6p	6p	NN	O
on	on	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
IL-6	IL-6	NNP	O
and	and	CC	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
production	production	NN	O
,	,	,	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
with	with	IN	O
LPS	LPS	NNP	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
compound	compound	NN	O
6p	6p	NNP	O
for	for	IN	O
24âh	24âh	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
levels	level	NNS	O
of	of	IN	O
IL-6	il-6	JJ	O
and	and	CC	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
in	in	IN	O
the	the	DT	O
supernatant	supernatant	JJ	O
were	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
ELISA	ELISA	NNP	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
,	,	,	O
LPS	LPS	NNP	O
stimulation	stimulation	NN	O
significantly	significantly	RB	O
elevated	elevate	VBD	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
and	and	CC	O
IL-6	il-6	JJ	O
.	.	.	O

After	after	IN	O
treatment	treatment	NN	O
with	with	IN	O
compound	compound	NNP	O
6p	6p	NNP	O
,	,	,	O
the	the	DT	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
increase	increase	NN	O
in	in	IN	O
IL-6	il-6	JJ	O
and	and	CC	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
levels	level	NNS	O
was	be	VBD	O
inhibited	inhibit	VBN	O
in	in	IN	O
a	a	DT	O
concentration	concentration	NN	O
-	-	HYPH	O
dependent	dependent	JJ	O
manner	manner	NN	O
.	.	.	O

Even	even	RB	O
at	at	IN	O
low	low	JJ	O
concentrations	concentration	NNS	O
3âÂµM	3ââµm	CD	O
,	,	,	O
6p	6p	PRP	O
significantly	significantly	RB	O
inhibited	inhibit	VBD	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
these	these	DT	O
two	two	CD	O
inflammatory	inflammatory	JJ	O
factors	factor	NNS	O
pâ<â.001	pâ<â.001	NNP	O
.	.	.	O

The	the	DT	O
pro	pro	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
mediator	mediator	NN	O
NO	no	DT	O
plays	play	VBZ	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
inflammation	inflammation	NN	O
-	-	HYPH	O
related	relate	VBN	O
diseases	disease	NNS	O
and	and	CC	O
its	-PRON-	PRP$	O
production	production	NN	O
is	be	VBZ	O
closely	closely	RB	O
related	relate	VBN	O
to	to	IN	O
the	the	DT	O
modulation	modulation	NN	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	cox-2	JJ	O
expression	expression	NN	B
.	.	.	O

Our	-PRON-	PRP$	O
results	result	NNS	O
show	show	VBP	O
that	that	IN	O
compound	compound	NN	O
6p	6p	NNS	O
can	can	MD	O
significantly	significantly	RB	O
inhibit	inhibit	VB	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
NO	no	UH	O
.	.	.	O

To	to	TO	O
establish	establish	VB	O
whether	whether	IN	O
this	this	DT	O
inhibitory	inhibitory	JJ	O
effect	effect	NN	O
was	be	VBD	O
associated	associate	VBN	O
with	with	IN	O
the	the	DT	O
reduced	reduced	JJ	O
expression	expression	NN	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	COX-2	NNP	O
in	in	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
RAW	RAW	NNP	O
264.7	264.7	CD	O
cells	cell	NNS	O
,	,	,	O
the	the	DT	O
levels	level	NNS	O
of	of	IN	O
these	these	DT	O
proteins	protein	NNS	O
were	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
western	western	JJ	O
blotting	blotting	NN	O
after	after	IN	O
exposure	exposure	NN	O
to	to	IN	O
LPS	LPS	NNP	O
for	for	IN	O
24âh	24âh	CD	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
or	or	CC	O
absence	absence	NN	O
of	of	IN	O
compound	compound	NN	O
6p	6p	NNS	O
7.5	7.5	CD	O
,	,	,	O
15	15	CD	O
,	,	,	O
and	and	CC	O
30âÂµM	30ââµm	CD	O
.	.	.	O

Celecoxib	Celecoxib	NNP	O
7.5âÂµM	7.5ââµm	CD	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
3	3	CD	O
,	,	,	O
LPS	LPS	NNP	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
stimulation	stimulation	NN	O
markedly	markedly	RB	O
increased	increase	VBD	O
COX-2	cox-2	NN	O
and	and	CC	O
iNOS	inos	VB	O
protein	protein	NN	O
expression	expression	NN	O
and	and	CC	O
compound	compound	NNP	O
6p	6p	NNS	O
inhibited	inhibit	VBD	O
this	this	DT	O
response	response	NN	O
pâ<â.001	pâ<â.001	NNP	O
by	by	IN	O
53.44	53.44	CD	O
%	%	NN	O
at	at	IN	O
15âÂµM	15ââµm	CD	O
and	and	CC	O
39.89	39.89	CD	O
%	%	NN	O
at	at	IN	O
30âÂµM	30ââµm	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
compound	compound	NNP	O
6p	6p	JJ	O
inhibited	inhibit	VBD	O
iNOS	inos	NN	O
protein	protein	NN	O
expression	expression	NN	O
in	in	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
cells	cell	NNS	O
in	in	IN	O
a	a	DT	O
dose	dose	RB	O
-	-	HYPH	O
dependent	dependent	JJ	O
manner	manner	NN	O
.	.	.	O

These	these	DT	O
results	result	NNS	O
suggest	suggest	VBP	O
that	that	IN	O
6p	6p	JJ	O
exerts	exert	VBZ	O
its	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
through	through	IN	O
inhibiting	inhibit	VBG	O
the	the	DT	O
expression	expression	NN	O
of	of	IN	O
iNOS	inos	NN	O
,	,	,	O
and	and	CC	O
COX-2	COX-2	VBN	O
by	by	IN	O
LPS	LPS	NNP	O
in	in	IN	O
macrophages	macrophage	NNS	O
.	.	.	O

Compound	Compound	NNP	O
6p	6p	NNP	O
inhibited	inhibit	VBD	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
inflammatory	inflammatory	JJ	O
response	response	NN	O
in	in	IN	O
RAW	RAW	NNP	O
264.7	264.7	CD	O

cells	cell	NNS	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
6p	6p	NN	O
7.5â30âÂµM	7.5â30ââµm	CD	O
and	and	CC	O
Celecoxib	Celecoxib	NNP	O
7.5âÂµM	7.5ââµm	CD	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

iNOS	iNOS	NNP	O
,	,	,	O
COX-2	COX-2	NNP	O
and	and	CC	O
GAPDH	GAPDH	NNP	O
proteins	protein	NNS	O
expression	expression	NN	O
were	be	VBD	O
detected	detect	VBN	O
by	by	IN	O
Western	western	JJ	O
blot	blot	NN	O
analysis	analysis	NN	O
.	.	.	O

Total	total	JJ	O
cellular	cellular	JJ	O
proteins	protein	NNS	O
were	be	VBD	O
prepared	prepare	VBN	O
and	and	CC	O
analysed	analyse	VBN	O
by	by	IN	O
Western	western	JJ	O
blotting	blotting	NN	O
.	.	.	O

Results	result	NNS	O
are	be	VBP	O
the	the	DT	O
meanâÂ±âSD	meanâÂ±âSD	NNP	O
,	,	,	O
nâ=â3	nâ=â3	NNP	O
.	.	.	O

#	#	$	O
#	#	$	O
#	#	$	O
pâ<â.001	pâ<â.001	NNS	O
,	,	,	O
vs.	vs.	IN	O
Control	Control	NNP	O
.	.	.	O

*	*	NFP	O
pâ<â.05	pâ<â.05	NNP	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
pâ<â.01	pâ<â.01	NNP	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
*	*	NFP	O
pâ<â.001	pâ<â.001	CD	O
vs.	vs.	IN	O
LPS	LPS	NNP	O
alone	alone	RB	O
.	.	.	O

As	as	IN	O
upstream	upstream	JJ	O
proteins	protein	NNS	O
,	,	,	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
the	the	DT	O
MAPK	MAPK	NNP	O
family	family	NN	O
of	of	IN	O
proteins	protein	NNS	O
is	be	VBZ	O
closely	closely	RB	O
related	relate	VBN	O
to	to	IN	O
and	and	CC	O
plays	play	VBZ	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
the	the	DT	O
expression	expression	NN	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	COX-2	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
release	release	NN	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
factors	factor	NNS	O
in	in	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
inflammatory	inflammatory	JJ	O
responses	response	NNS	B
,	,	,	B
.	.	.	O

To	to	TO	O
find	find	VB	O
the	the	DT	O
molecular	molecular	JJ	O
target	target	NN	O
of	of	IN	O
compound	compound	NN	O
6p	6p	JJ	O
further	further	JJ	O
upstream	upstream	NN	O
of	of	IN	O
the	the	DT	O
MAPK	MAPK	NNP	O
signalling	signalling	NN	O
pathway	pathway	NN	O
,	,	,	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
compound	compound	NN	O
6p	6p	NNS	O
on	on	IN	O
the	the	DT	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
ERK	ERK	NNP	O
,	,	,	O
JNK	JNK	NNP	O
,	,	,	O
and	and	CC	O
p38	p38	NNP	O
MAPKs	MAPKs	NNPS	O
in	in	IN	O
RAW	raw	JJ	O
264.7	264.7	CD	O
cells	cell	NNS	O
were	be	VBD	O
assessed	assess	VBN	O
by	by	IN	O
western	western	JJ	O
blotting	blotting	NN	O
.	.	.	O

Celecoxib	Celecoxib	NNP	O
7.5âÂµM	7.5ââµm	CD	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

As	as	IN	O
expected	expect	VBN	O
,	,	,	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
p38	p38	NN	O
,	,	,	O
JNK	JNK	NNP	O
,	,	,	O
and	and	CC	O
ERK	ERK	NNP	O
increased	increase	VBD	O
after	after	IN	O
LPS	LPS	NNP	O
stimulation	stimulation	NN	O
.	.	.	O

Compound	Compound	NNP	O
6p	6p	NNP	O
markedly	markedly	RB	O
diminished	diminish	VBD	O
the	the	DT	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
JNK	JNK	NNP	O
pâ<â.001	pâ<â.001	NNP	O
,	,	,	O
ERK	ERK	NNP	O
pâ<â.001	pâ<â.001	NNP	O
and	and	CC	O
p38	p38	NNP	O
pâ<â.01	pâ<â.01	NNP	O
MAPKs	mapk	VBZ	O
at	at	IN	O
30âÂµM	30ââµm	CD	O
Figure	Figure	NNP	O
4(AâC	4(aâc	CD	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
compound	compound	NN	O
6p	6p	NNS	O
7.5	7.5	CD	O
,	,	,	O
15	15	CD	O
,	,	,	O
and	and	CC	O
30âÂµM	30ââµm	CD	O
inhibited	inhibit	VBD	O
the	the	DT	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
JNK	JNK	NNP	O
and	and	CC	O
ERK	ERK	NNP	O
in	in	IN	O
a	a	DT	O
concentration	concentration	NN	O
-	-	HYPH	O
dependent	dependent	JJ	O
manner	manner	NN	O
.	.	.	O

These	these	DT	O
results	result	NNS	O
suggest	suggest	VBP	O
that	that	IN	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effect	effect	NN	O
of	of	IN	O
compound	compound	NN	O
6p	6p	NNS	O
might	may	MD	O
be	be	VB	O
associated	associate	VBN	O
with	with	IN	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
effects	effect	NNS	O
on	on	IN	O
the	the	DT	O
MAPK	MAPK	NNP	O
signalling	signal	VBG	O
pathways	pathway	NNS	O
.	.	.	O

Compound	Compound	NNP	O
6p	6p	CD	O
inhibited	inhibit	VBD	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
inflammatory	inflammatory	JJ	O
response	response	NN	O
in	in	IN	O
RAW	RAW	NNP	O
264.7	264.7	CD	O

cells	cell	NNS	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
6p	6p	NN	O
7.5â30âÂµM	7.5â30ââµm	CD	O
and	and	CC	O
Celecoxib	Celecoxib	NNP	O
7.5âÂµM	7.5ââµm	CD	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

The	the	DT	O
levels	level	NNS	O
of	of	IN	O
p	p	NN	O
-	-	HYPH	O
p38	p38	NNP	O
/	/	SYM	O
P38	P38	NNP	O
,	,	,	O
p	p	NNP	O
-	-	HYPH	O
ERK	ERK	NNP	O
/	/	SYM	O
ERK	ERK	NNP	O
,	,	,	O
p	p	NNP	O
-	-	HYPH	O
JNK	JNK	NNP	O
/	/	SYM	O
JNK	JNK	NNP	O
and	and	CC	O
GAPDH	GAPDH	NNP	O
proteins	protein	NNS	O
,	,	,	O
and	and	CC	O
their	-PRON-	PRP$	O
phosphorylated	phosphorylated	JJ	O
forms	form	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
using	use	VBG	O
Western	western	JJ	O
blotting	blotting	NN	O
.	.	.	O

Total	total	JJ	O
cellular	cellular	JJ	O
proteins	protein	NNS	O
were	be	VBD	O
prepared	prepare	VBN	O
and	and	CC	O
analysed	analyse	VBN	O
by	by	IN	O
Western	western	JJ	O
blotting	blotting	NN	O
.	.	.	O

Results	result	NNS	O
are	be	VBP	O
the	the	DT	O
meanâÂ±âSD	meanâÂ±âSD	NNP	O
,	,	,	O
nâ=â3	nâ=â3	NNP	O
.	.	.	O

#	#	$	O
#	#	$	O
#	#	$	O
pâ<â.001	pâ<â.001	NNS	O
,	,	,	O
vs.	vs.	IN	O
Control	Control	NNP	O
.	.	.	O

*	*	NFP	O
pâ<â.05	pâ<â.05	NNP	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
pâ<â.01	pâ<â.01	NNP	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
*	*	NFP	O
pâ<â.001	pâ<â.001	CD	O
vs.	vs.	IN	O
LPS	LPS	NNP	O
alone	alone	RB	O
.	.	.	O

To	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
of	of	IN	O
compound	compound	NNP	O
6p	6p	NNP	O
in	in	IN	O
vivo	vivo	NNP	O
,	,	,	O
a	a	DT	O
carrageenan	carrageenan	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
mouse	mouse	NN	O
paw	paw	NNP	O
oedema	oedema	NNP	O
model	model	NN	O
was	be	VBD	O
used	use	VBN	B
,	,	,	B
.	.	.	O

Each	each	DT	O
test	test	NN	O
compound	compound	NN	O
lead	lead	NN	O
compound	compound	NNP	O
D1	d1	NN	O
,	,	,	O
6p	6p	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
positive	positive	JJ	O
controls	control	NNS	O
ibuprofen	ibuprofen	NNP	O
and	and	CC	O
celecoxib	celecoxib	NNP	O
was	be	VBD	O
administered	administer	VBN	O
orally	orally	RB	O
at	at	IN	O
a	a	DT	O
dose	dose	NN	O
of	of	IN	O
25âmg	25âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
body	body	NN	O
weight	weight	NN	O
prior	prior	RB	O
to	to	IN	O
the	the	DT	O
induction	induction	NN	O
of	of	IN	O
inflammation	inflammation	NN	O
by	by	IN	O
carrageenan	carrageenan	NNP	O
0.1âml	0.1âml	NNP	O
injection	injection	NN	O
.	.	.	O

The	the	DT	O
paw	paw	NN	O
volume	volume	NN	O
was	be	VBD	O
measured	measure	VBN	O
over	over	IN	O
5âh	5âh	CD	O
at	at	IN	O
0	0	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
3	3	CD	O
,	,	,	O
and	and	CC	O
5âh	5âh	CD	O
and	and	CC	O
the	the	DT	O
percent	percent	NN	O
inhibition	inhibition	NN	O
of	of	IN	O
oedema	oedema	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
Table	table	NN	O
2	2	CD	O
.	.	.	O

Inhibition	inhibition	NN	O
of	of	IN	O
paw	paw	NN	O
swelling	swelling	NN	O
was	be	VBD	O
the	the	DT	O
highest	high	JJS	O
in	in	IN	O
mice	mouse	NNS	O
3âh	3âh	CD	O
after	after	IN	O
carrageenan	carrageenan	NNP	O
administration	administration	NNP	O
by	by	IN	O
all	all	PDT	O
the	the	DT	O
tested	test	VBN	O
compounds	compound	NNS	O
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
noteworthy	noteworthy	JJ	O
that	that	IN	O
compound	compound	NN	O
6p	6p	NNS	O
displayed	display	VBD	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effects	effect	NNS	O
that	that	WDT	O
were	be	VBD	O
significantly	significantly	RB	O
greater	great	JJR	O
than	than	IN	O
those	those	DT	O
of	of	IN	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
D1	d1	NN	O
42.81	42.81	CD	O
%	%	NN	O
,	,	,	O
pâ<â.01	pâ<â.01	NNP	O
and	and	CC	O
ibuprofen	ibuprofen	NNP	O
39.30	39.30	CD	O
%	%	NN	O
,	,	,	O
pâ<â.01	pâ<â.01	NNP	O
,	,	,	O
but	but	CC	O
slightly	slightly	RB	O
lesser	less	JJR	O
than	than	IN	O
those	those	DT	O
of	of	IN	O
celecoxib	celecoxib	NNP	O
58.34	58.34	CD	O
%	%	NN	O
,	,	,	O
pâ<â.05	pâ<â.05	FW	O
Figure	figure	NN	O
5	5	CD	O
.	.	.	O

The	the	DT	O
inhibited	inhibited	JJ	O
paw	paw	NN	O
swelling	swell	VBG	O
actives	active	NNS	O
of	of	IN	O
lead	lead	NN	O
compound	compound	NN	O
D1	d1	NN	O
,	,	,	O
6p	6p	JJ	O
and	and	CC	O
positive	positive	JJ	O
control	control	NN	O
drugs	drug	NNS	O
25âmg	25âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
in	in	IN	O
a	a	DT	O
carrageenan	carrageenan	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
mouse	mouse	NN	O
paw	paw	NNP	O
oedema	oedema	NN	O
model	model	NN	O
after	after	IN	O
3âh	3âh	CD	O
of	of	IN	O
oral	oral	NNP	O
administration	administration	NN	O
.	.	.	O

*	*	NFP	O
*	*	NFP	O
pâ<â.01	pâ<â.01	NNP	O
,	,	,	O
vs.	vs.	FW	O
D1	d1	NN	O
;	;	:	O
#	#	$	O
#	#	$	O
pâ<â.01	pâ<â.01	NNP	O
,	,	,	O
vs.	vs.	IN	O
Ibuprofen	Ibuprofen	NNP	O
;	;	:	O
$	$	$	O
pâ<â.05	pâ<â.05	NNPS	O
,	,	,	O
vs.	vs.	FW	O
Celecoxib	Celecoxib	NNP	O
.	.	.	O

The	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
and	and	CC	O
ulcerogenic	ulcerogenic	JJ	O
activity	activity	NN	O
in	in	IN	O
vivo	vivo	NN	O
.	.	.	O

Values	value	NNS	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
the	the	DT	O
meanâÂ±âS.	meanââ±âs.	NN	O
D	D	NNP	O
nâ=â4	nâ=â4	NNP	O
.	.	.	O

Control	control	NN	O
:	:	:	O
0.5	0.5	CD	O
%	%	NN	O
sodium	sodium	NN	O
CMC	CMC	NNP	O
solution	solution	NN	O
in	in	IN	O
distilled	distil	VBN	O
water	water	NN	O
25âml	25âml	CD	O
/	/	SYM	O
kg	kg	NNP	O
,	,	,	O
p.o	p.o	NNP	O
.	.	NNP	O

.	.	.	O

Compounds	compound	NNS	O
and	and	CC	O
positive	positive	JJ	O
drugs	drug	NNS	O
were	be	VBD	O
administered	administer	VBN	O
at	at	IN	O
a	a	DT	O
dose	dose	NN	O
of	of	IN	O
25âmg	25âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
,	,	,	O
p.o	p.o	NNP	O
.	.	NNP	O

in	in	IN	O
0.5	0.5	CD	O
%	%	NN	O
sodium	sodium	NN	O
CMC	CMC	NNP	O
solution	solution	NN	O
.	.	.	O

In	in	IN	O
order	order	NN	O
to	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
damage	damage	NN	O
of	of	IN	O
the	the	DT	O
synthesised	synthesise	VBN	O
compound	compound	NN	O
to	to	IN	O
the	the	DT	O
gastric	gastric	JJ	O
mucosa	mucosa	NNP	O
,	,	,	O
acute	acute	JJ	O
ulcerogenic	ulcerogenic	JJ	O
studies	study	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
for	for	IN	O
the	the	DT	O
most	most	JJS	O
biologically	biologically	RB	O
active	active	JJ	O
synthesised	synthesise	VBN	O
compound	compound	NNP	O
6p	6p	NNS	O
,	,	,	O
lead	lead	JJ	O
compound	compound	NNP	O
D1	d1	NN	O
,	,	,	O
ibuprofen	ibuprofen	NNP	O
and	and	CC	O
celecoxib	celecoxib	VB	O
as	as	IN	O
standard	standard	JJ	O
was	be	VBD	O
evaluated	evaluate	VBN	O
using	use	VBG	O
the	the	DT	O
reference	reference	NN	O
reported	report	VBD	O
procedure	procedure	NN	B
.	.	.	O

Results	result	NNS	O
are	be	VBP	O
presented	present	VBN	O
in	in	IN	O
Table	table	NN	O
2	2	CD	O
as	as	IN	O
%	%	NN	O
ulceration	ulceration	NN	O
.	.	.	O

The	the	DT	O
ulceration	ulceration	NN	O
effect	effect	NN	O
of	of	IN	O
compound	compound	NNP	O
6p	6p	CD	O
was	be	VBD	O
stronger	strong	JJR	O
than	than	IN	O
the	the	DT	O
selective	selective	JJ	O
COX-2	cox-2	JJ	O
inhibitor	inhibitor	NN	O
celecoxib	celecoxib	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
weaker	weak	JJR	O
than	than	IN	O
the	the	DT	O
non	non	JJ	O
-	-	JJ	O
selective	selective	JJ	O
COX-2	cox-2	JJ	O
inhibitor	inhibitor	NN	O
ibuprofen	ibuprofen	NN	O
that	that	WDT	O
showed	show	VBD	O
100	100	CD	O
%	%	NN	O
ulceration	ulceration	NN	O
.	.	.	O

In	in	IN	O
summary	summary	NN	O
,	,	,	O
we	-PRON-	PRP	O
designed	design	VBD	O
,	,	,	O
synthesised	synthesise	VBN	O
,	,	,	O
and	and	CC	O
characterised	characterise	VBD	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
5-alkyl-4-oxo-4,5-dihydro	5-alkyl-4-oxo-4,5-dihydro	CD	O
-	-	HYPH	O
triazoloquinoxaline-1-carboxamide	triazoloquinoxaline-1-carboxamide	NNP	O
derivatives	derivative	NNS	O
using	use	VBG	O
by	by	IN	O
1H	1h	JJ	O
-	-	HYPH	O
NMR	NMR	NNP	O
,	,	,	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
and	and	CC	O
HRMS	HRMS	NNP	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
tested	test	VBN	O
compounds	compound	NNS	O
inhibited	inhibit	VBD	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
NO	no	DT	O
production	production	NN	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
macrophages	macrophage	NNS	O
.	.	.	O

Among	among	IN	O
them	-PRON-	PRP	O
,	,	,	O
compound	compound	NNP	O
6p	6p	NNS	O
exhibited	exhibit	VBD	O
the	the	DT	O
most	most	RBS	O
significant	significant	JJ	O
activity	activity	NN	O
and	and	CC	O
was	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
D1	d1	NN	O
.	.	.	O

Investigation	investigation	NN	O
of	of	IN	O
the	the	DT	O
mechanisms	mechanism	NNS	O
underlying	underlie	VBG	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
of	of	IN	O
compound	compound	NNP	O
6p	6p	NNPS	O
showed	show	VBD	O
that	that	IN	O
it	-PRON-	PRP	O
inhibits	inhibit	VBZ	O
the	the	DT	O
expression	expression	NN	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	COX-2	NNP	O
and	and	CC	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
NO	NO	NNP	O
,	,	,	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
and	and	CC	O
IL-6	il-6	JJ	O
by	by	IN	O
suppressing	suppress	VBG	O
the	the	DT	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
MAPK	MAPK	NNP	O
signalling	signalling	NN	O
pathway	pathway	NN	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
compound	compound	NN	O
6p	6p	NNS	O
displayed	display	VBD	O
more	more	RBR	O
prominent	prominent	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
and	and	CC	O
weaker	weak	JJR	O
ulceration	ulceration	NN	O
than	than	IN	O
the	the	DT	O
positive	positive	JJ	O
control	control	NN	O
ibuprofen	ibuprofen	NN	O
in	in	IN	O
the	the	DT	O
in	in	IN	O
vivo	vivo	NNP	O
acute	acute	NNP	O
inflammatory	inflammatory	JJ	O
model	model	NN	O
.	.	.	O

These	these	DT	O
findings	finding	NNS	O
indicate	indicate	VBP	O
that	that	IN	O
compound	compound	NN	O
6p	6p	NNS	O
could	could	MD	O
serve	serve	VB	O
as	as	IN	O
a	a	DT	O
promising	promising	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
agent	agent	NN	O
and	and	CC	O
warrants	warrant	NNS	O
further	further	JJ	O
studies	study	NNS	O
.	.	.	O

